Shell Stocks; Reverse Mergers; Acquisitions; Zombies; Greys; & All "Other" Plays

[Potse]

adijas...CLCL...increased my position.....

'We are redoing the websites calcol.com and kulongenergy.com but relying more on the pinksheets.com and Twitter @EnergyKulong and Facebook: KULONG ENERGY BEVERAGE COMPANY INC. for timely release of breaking news about the company's new business and exciting new products now being introduced and successfully sold in the USA (besides our China business). We have global trademarks and own the formulas and all distribution rights and hope to be selling across the USA and internationally (besides USA and China) soon. In my personal opinion the stock is greatly undervalued. I personally would go as high as 10-15 cents currently, as the stock has historical trade between 15-50 cents, all time high $1.15 in November 1999, all time low now.

I think you will be happy you invested with us as our new products are liked by everyone who tries them! They are paying $2.00-$3.50 per can and we are earning $1.00 per can. The future looks very bright!

We will do filings. But it will take some time because we are on a major pivot to selling in the USA and then fully audited and possibly fully reporting on some exchange if possible. Audits are very problematic in China but not in USA.

OS is 99.5 million. Much of the stock restricted and/or closely held. Dont know float. I am neither a buyer nor seller. Urge all our investors to accumulate. Make your own evaluation.'

I've increased my CLCL position at the sub-penny level. Although its a high-risk investment because of the non-filing status (and the possibility the SEC might eventually target these types of companies for suspension/revocation), I consider CLCL around this sub-penny to penny price area to be close to a "no-brainer" kind of situation. The increase in social media activity by the company/Kaplan (which initially started in early 2015 and has now accelerated dramatically in recent weeks) seems to be building/pointing to a substantial increase in the share price at some point.

If Kaplan follows through on a decent redesign of the company's websites, that should significantly help investors' perceptions of the company. A fully-updated and more "aesthetically pleasing" corporate website would be a very welcome development, since the quality of the CLCL website has long been a major turn off for prospective investors.

Kaplan's statement that the outstanding share count is still under 100M is extremely interesting. That would mean that there has been basically no increase in the outstanding share count for about decade or more (from around the time it did some private placements to complete/expand the soft drink business/facilities in China).

If I recall correctly the last public information on CLCL's financings showed the company had sold about $4.5M in preferred shares (about 10-12 years or so ago) which had an interest rate of 8% and were convertible at 20 cents. The interest was payable in cash or shares, but I don't recall if any terms of the share payment for interest was disclosed. The company also had a class of preferred shares that were outstanding and convertible into 10M shares.

So, depending on whether there were any changes to the conversion price over the years, and whether the company has been accruing the interest payments or paying off the interest in cash, I would assume the fully-diluted share count is probably north of 130M. Regardless of what the fully-diluted count might be, CLCL could turn into a pretty nice momentum type stock at some point. Sometimes it seems like it is easy to pick up a nice chunk of shares, but other times it seems like relatively minor buying pressure can move the price higher very quickly.

Kaplan's acknowledgement (in early 2015 and again in his 2016 postings) that CLCL has restarted its development stage pharma business makes for a potentially huge wildcard. Particularly if the company is doing any additional research/development in the area of the anti-tumor drug it was working on.....

Calcol, a development stage company, was
originally a holding company for pharmaceutical
patents and products. It pioneered the pharmaceutical
development of delta-9-tetrahydrocannabinol (THC),
the active ingredient in medicinal marijuana, for the
treatment of nausea associated with cancer
chemotherapy and loss of appetite associated with
AIDS. The company also developed and tested (in vitro
at the Salk Institute, and in vivo in mouse models in
collaboration with the National Cancer Institute) a
derivative of THC (THC-mustard) as potential sitespecific
alkylating agent (anti-tumor drug) with
antinausea properties. Mr. Kaplan holds one patent,
and has published two abstracts and two scientific
papers on this research. Calcol sold non-exclusive
distribution rights for its THC/dronabinol product to
Barr Laboratories in l988 based on a 15 year agreement.
However Calcol retains some rights for the THC/
dronabinol product.

http://www.asiabiotech.com/publication/apbn/05/english/preserved-docs/0516/0355_0365.pdf